What do systematic reviews say?

PDEI plus alpha‐blocker vs alpha‐blocker

PDEI plus alpha‐blocker probably leads to higher adverse effects compared with alpha‐blockers alone (moderate certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 2.81 [1.53, 5.17]
  4 studies · 194 participants
  Moderate